Four of the country's largest physician organizations released a coordinated set of fall vaccine recommendations this week, filling a gap left by the federal advisory committee that normally does that work. The guidance covers influenza, COVID-19, and respiratory syncytial virus for the 2026-2027 respiratory virus season.
The American Medical Association organized the effort with the Vaccine Integrity Project, based at the University of Minnesota's Center for Infectious Disease Research and Policy. The recommendations come from the American Academy of Family Physicians, the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the Infectious Diseases Society of America, and are posted on a new AMA website, SpreadTheFacts.org, alongside the coordinated fall immunization recommendations.
For households, this changes where the answer comes from, not whether one exists. Anyone booking a flu shot, a COVID-19 dose or an RSV vaccine in the coming weeks now has age-specific guidance from the same professional bodies that certify their own doctors.
Where the Advice Now Comes From
The reason the societies stepped in is procedural. The Centers for Disease Control and Prevention and its vaccine advisory committee traditionally issue this guidance, but the committee's recommendations have been effectively paused since March, when a federal district court in Massachusetts invalidated changes Health Secretary Robert F. Kennedy Jr. made to the panel. That case is on appeal.
More than one immunization schedule is now in circulation. Federal childhood vaccine recommendations were narrowed in January and stayed by a federal judge in Boston in March, leaving the pre-June 2025 schedule as the operative federal one.
The CDC has not gone entirely quiet. On Tuesday, the agency updated its interim clinical considerations for influenza vaccines, stating that because of legal uncertainties, the seasonal influenza recommendations from the July 2025 immunization schedule remain in effect for the 2026-2027 season. That is an unusual sentence for a routine clinical document.
Inside the 2026-2027 Recommendations
On influenza, the groups are aligned, and the message is broad. Vaccination is recommended for everyone 6 months and older without a medical contraindication. Adults 65 and older should preferentially receive an enhanced product, meaning high dose, adjuvanted, recombinant or mRNA, though the family physicians say patients should not delay vaccination to obtain one.
COVID-19 guidance is more layered. The family physicians' fall vaccine recommendations cover all adults 19 and older, with added weight for patients 65 and older, patients at increased risk of severe infection, and patients who have never been vaccinated. Adults 65 and older should receive a second dose of the updated vaccine six months after the first. The academy recommends vaccination for all children 6 to 23 months and a risk-based single-dose approach for ages 2 to 18, which it says aligns with the pediatricians' 2026 recommendation. Vaccination is recommended in any trimester of pregnancy and during lactation, aligning with the obstetricians' group.
RSV guidance is the most tightly targeted of the three. The groups support a one-time vaccine for adults 75 and older and for adults 50 to 74 at increased risk, and recommend RSV vaccination for immunocompromised adults and adolescents. Pregnant patients should receive the RSV vaccine at 32 to 36 weeks during the September-to-March window, which is longer than the previous September-to-January period. Infants younger than 8 months without maternal protection should receive nirsevimab or clesrovimab, and high-risk children 8 through 19 months entering a second season should receive nirsevimab.
The infectious disease specialists recommend COVID-19 vaccination for immunocompromised patients 6 months and older, and suggest discussing an additional dose two to six months after the first for people with high-risk conditions.
The Burden These Shots Are Meant to Reduce
The numbers behind the guidance are large. The CDC estimated that influenza was associated with 390,000 to 800,000 hospitalizations during the 2025-2026 season. Its preliminary RSV estimates for the same season put the burden at 2.8 million to 5.8 million outpatient visits, 170,000 to 340,000 hospitalizations and 9,900 to 25,000 deaths.
The independent evidence review behind the recommendations reported effect sizes rather than promises. Flu vaccination was tied to a 31 percent lower risk of influenza-associated hospitalization in adults 65 and older. COVID-19 vaccination was tied to a 53 percent lower risk of hospitalization in the same age group. RSV vaccine effectiveness against hospitalization in adults 60 and older ranged from 69 to 83 percent across single-season estimates.
Risk is not evenly distributed. Infants under 6 months, adults over 65, pregnant patients, people with chronic heart or lung disease, and people with weakened immune systems carry the heaviest share. A healthy 30-year-old office worker faces a different calculation than a caregiver for an 80-year-old parent, and the recommendations reflect that.
Bruce Gellin, chair of the Vaccine Integrity Project board of advisors, said at a briefing that the breakdown of the federal process cannot be allowed to create "a vacuum in evidence-based vaccine guidance." He encouraged people hearing conflicting messages to examine the process behind the recommendations.
Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security who was not part of the review, told reporters that the shift itself is the story, because the recommendations are now coming from professional societies rather than the federal government.
Coverage, Cost and the Pharmacy Counter
The practical friction is insurance. Under the Affordable Care Act, health plans must cover, without cost sharing, immunizations that the federal advisory committee recommends and the CDC director adopts. The Vaccines for Children program works on the same hinge, since federal contracts follow a committee resolution. A recommendation from the four societies triggers neither.
There is a partial cushion. AHIP, the health insurance trade group, said in a statement updated in May that member plans will continue covering all federally recommended immunizations with no cost sharing through the end of 2027. That is a voluntary commitment from a trade association, not a legal mandate.
The American Immunization Registry Association is translating the influenza, RSV, and COVID-19 recommendations into structured guidance for immunization information systems and electronic health records, with that material expected by mid-September. Until then, clinical decision support in many systems will lag the printed advice, and the project's immunization resources remain the clearest public reference point.
Reasonable steps now: call the plan's member services line and ask whether a specific shot is covered without cost sharing before booking, ask the pharmacist which formulation is in stock, and bring a vaccination record. Adults without coverage can ask county health departments and federally qualified health centers about low-cost clinics.
Nobody should stop or start a prescription medication based on vaccine timing without talking to a clinician. People with immune-suppressing conditions should ask about spacing doses around treatment.
Several things remain unresolved. There is no confirmed date for an advisory committee meeting that could produce a federal 2026-2027 recommendation. Real-world effectiveness data for this season's COVID-19 formula does not yet exist. Whether insurers uniformly follow society guidance is untested, and the underlying research links for the season will keep updating as the winter progresses.
The bottom line for most households is unglamorous. Flu vaccination is recommended broadly, COVID-19 and RSV guidance depends on age, pregnancy and health conditions, and the fastest way to sort it out is a short conversation with a clinician or pharmacist before respiratory season builds.
Key Questions Answered
Who issued these recommendations? The American Medical Association and the Vaccine Integrity Project convened four societies: family physicians, pediatricians, obstetricians and gynecologists, and infectious disease specialists.
Why did doctors' groups do this instead of the CDC? Federal vaccine recommendations have been effectively paused since a March court ruling invalidated changes to the advisory committee. The appeal is pending.
Who should get a flu shot? The groups recommend influenza vaccination for everyone 6 months and older without a contraindication, with enhanced products preferred for adults 65 and older.
Who should get an RSV vaccine? Adults 75 and older, adults 50 to 74 at increased risk, immunocompromised adults and adolescents, and pregnant patients at 32 to 36 weeks during the September-to-March window.
Will insurance still cover these shots? Often yes, but the usual legal trigger is unsettled. One large insurer group has pledged continued coverage. Call the plan before booking.
Does this mean the CDC recommends something different? The CDC has said the July 2025 influenza recommendations remain in effect this season. The societies go further in some pediatric and adult COVID-19 categories.
What should someone do if they are unsure? Bring a vaccination record to a clinician or pharmacist and ask which of the three vaccines applies given age, pregnancy status and health conditions.
